Critères d'inclusion : . Age < or = 18 years, patients aged 75 years or more will benefit from a geriatric assessment.
. Advanced or metastatic urothelial cancer confirmed histologically or cytologically.
. Patients liable to receive a first -line chemotherapy for advanced or metastatic urothelial carcinoma.
. Measurable disease according to RECIST criteria V1.1.
. Patients who received neoadjuvant or adjuvant chemotherapy based on platinum salt must have completed treatment at least 6 months before entering the study.
. Performance status < or = 2.
. Life expectancy > 3 months.
. Patients with creatinine clearance between 40 and 60 ml / min ( according to Cockcroft and Gault ).
. Patients having no contra-indication to overhydration.
. Satisfactory hematological tests: Neutrophils > 1.5 G / l Platelets > 150 G / l , hemoglobin ≥ 10 g / dl.
. Satisfactory liver function tests: total bilirubin < 1.5 x ULN (upper limit of normal), AST (aspartate aminotransferase) and ALT (alanine aminotransferase)
Critères de non-inclusion : . Any concomitant or previous malignancy within 5 years prior to the study ( with the exception of basal cell or squamous cell carcinoma in situ).
. Pregnant or lactating women.
. Patients with brain metastases or meningeal or symptoms suggestive of such secondary locations.
. Bisphosphonate or Denosumab treatment initiated within 28 days prior to randomization into the study or patient who have started such treatment during the study ( a bisphosphonate or denosumab treatment initiated within a period longer than 28 days before randomization may be continued without change during the study ).
. Other concomitant cancer (radiation therapy, radiopharmaceutical agent chemotherapy).
. Patients with uncontrolled infection.
. Patients with peripheral neuropathy grade> 1, whatever the origin or patients with hearing loss.
. Patient with unstable disease (eg: unstable diabetes, poorly controlled hypertension , congestive heart failure or myocardial infarction within 3 months prior to study entry).
. Known hypersensitivity to study drugs.
. Treatment with any other investigational drug within 30 days before inclusion.
. Any psychological condition , familial, sociological or geographical not to comply with medical monitoring and / or procedures in the study protocol.
. Patient protected by law.